Publication Name	World Journal of Ophthalmology
Manuscript ID	16150
Country

Received	2014-12-30 09:23
Peer-Review Started	2014-12-30 20:15
To Make the First Decision	2015-01-20 13:29
Return for Revision	2015-02-03 20:20
Revised	2015-02-21 07:34
Second Decision	2015-04-26 20:08
Accepted by Journal Editor-in-Chief	2015-04-27 04:41
Accepted by Executive Editor-in-Chief	2015-05-06 14:17
Articles in Press	2015-05-06 14:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-07-18 18:15
Publish the Manuscript Online	2015-08-17 11:09

ISSN	2218-6239 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Ophthalmology
Manuscript Type	Editorial
Article Title	Approved pharmacotherapy for macular edema secondary to branch retinal vein occlusion: A review of randomized controlled trials in dexamethasone implants, ranibizumab, and aflibercept
Manuscript Source	Invited Manuscript
All Author List	Jia-Kang Wang
Funding Agency and Grant Number
Corresponding Author	Dr. Jia-Kang Wang, MD, Department of Ophthalmology, Far Eastern Memorial Hospital, 21, Sec. 2, Nan-Ya South Road, Pan-Chiao District, New Taipei City, Taipei 220, Taiwan. jiakangw@yahoo.com.tw
Key Words	Branch retinal vein occlusion; Intravitreal injection; Aflibercept; Ranibizumab; Macular edema; Ozurdex
Core Tip	There are three approved pharmacotherapies for treating macular edema secondary to branch retinal vein occlusion (BRVO), including corticosteroids (dexamethasone implants) and anti-vascular endothelial growth factor (VEGF) (ranibizumab and aflibercept). They all show superior ability to improve vision and reduce macular thickness, comparing with sham injections or macular grid laser treatment. There is no severe ocular or systemic adverse reaction reported in studies associated with anti-VEGF for macular edema after BRVO. Intraocular pressure elevation and cataract aggravation should be addressed after intravitreal dexamethasone implants. Single intravitreal dexamethasone implant had longer effective duration than two anti-VEGFs.
Publish Date	2015-08-17 11:09
Citation	Wang JK. Approved pharmacotherapy for macular edema secondary to branch retinal vein occlusion: A review of randomized controlled trials in dexamethasone implants, ranibizumab, and aflibercept. World J Ophthalmol 2015; 5(3): 106-109
URL	http://www.wjgnet.com/2218-6239/full/v5/i3/106.htm
DOI	http://dx.doi.org/10.5318/wjo.v5.i3.106

Full Article (PDF)	WJO-5-106.pdf
Full Article (Word)	WJO-5-106.doc
Manuscript File	16150-Review.doc
Answering Reviewers	16150-Answering reviewers.pdf
Audio Core Tip	16150-Audio core tip.wav
Conflict-of-Interest Disclosure Form	16150-Conflict-of-interest statement.pdf
Copyright License Agreement	16150-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	16150-Journal editor-in-chief review report.pdf
Peer-review Report	16150-Peer-review(s).pdf
Scientific Misconduct Check	16150-Scientific misconduct check.pdf
Scientific Editor Work List	16150-Scientific editor work list.pdf